| Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA DM Kurtz, J Soo, L Co Ting Keh, S Alig, JJ Chabon, BJ Sworder, A Schultz, ... Nature biotechnology 39 (12), 1537-1547, 2021 | 177 | 2021 |
| Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ... Cancer discovery 10 (3), 440-459, 2020 | 117 | 2020 |
| Inferring gene expression from cell-free DNA fragmentation profiles MS Esfahani, EG Hamilton, M Mehrmohamadi, BY Nabet, SK Alig, ... Nature biotechnology 40 (4), 585-597, 2022 | 76 | 2022 |
| Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma D Bararia, JA Hildebrand, S Stolz, S Haebe, S Alig, CP Trevisani, ... Cell reports 31 (5), 2020 | 62 | 2020 |
| Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles JC Hellmuth, A Louissaint Jr, M Szczepanowski, S Haebe, A Pastore, ... Blood, The Journal of the American Society of Hematology 132 (16), 1695-1702, 2018 | 60 | 2018 |
| Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas BJ Sworder, DM Kurtz, SK Alig, MJ Frank, N Shukla, A Garofalo, ... Cancer Cell 41 (1), 210-225. e5, 2023 | 51 | 2023 |
| Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma S Alig, CW Macaulay, DM Kurtz, U Dührsen, A Hüttmann, C Schmitz, ... Journal of Clinical Oncology 39 (23), 2605-2616, 2021 | 42 | 2021 |
| ARNO regulates VEGF-dependent tissue responses by stabilizing endothelial VEGFR-2 surface expression HK Mannell, J Pircher, DI Chaudhry, SKC Alig, EG Koch, R Mettler, U Pohl, ... Cardiovascular research 93 (1), 111-119, 2012 | 39 | 2012 |
| Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas JA Mutter, SK Alig, MS Esfahani, EM Lauer, J Mitschke, DM Kurtz, J Kühn, ... Journal of Clinical Oncology 41 (9), 1684-1694, 2023 | 38 | 2023 |
| Severe cytokine release syndrome after the first dose of B rentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (s ALCL): a case report and … SK Alig, M Dreyling, B Seppi, B Aulinger, L Witkowski, CT Rieger European Journal of Haematology 94 (6), 554-557, 2015 | 31 | 2015 |
| Impact of age on clinical risk scores in follicular lymphoma S Alig, V Jurinovic, A Pastore, S Haebe, C Schmidt, AK Zoellner, ... Blood Advances 3 (7), 1033-1038, 2019 | 26 | 2019 |
| The tyrosine phosphatase SHP-1 regulates hypoxia inducible factor-1α (HIF-1α) protein levels in endothelial cells under hypoxia SK Alig, Y Stampnik, J Pircher, R Rotter, E Gaitzsch, A Ribeiro, M Wörnle, ... PLoS One 10 (3), e0121113, 2015 | 26 | 2015 |
| Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma RC Lynch, CS Ujjani, C Poh, EH Warren, SD Smith, M Shadman, B Till, ... Blood, The Journal of the American Society of Hematology 141 (21), 2576-2586, 2023 | 24 | 2023 |
| Circulating DNA for molecular response prediction, characterization of resistance mechanisms and quantification of CAR T-cells during axicabtagene ciloleucel therapy B Sworder, DM Kurtz, C Macaulay, MJ Frank, S Alig, A Garofalo, B Sahaf, ... Blood 134, 550, 2019 | 18 | 2019 |
| Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma JA Mutter, S Alig, EM Lauer, MS Esfahani, J Mitschke, DM Kurtz, J Kühn, ... Blood 138 (Supplement 1), 6-6, 2021 | 17 | 2021 |
| Impact of age on genetics and treatment efficacy in follicular lymphoma S Alig, V Jurinovic, A Pastore, D Bararia, S Häbe, JC Hellmuth, R Kridel, ... Haematologica 103 (8), e364, 2018 | 15 | 2018 |
| The endothelial tyrosine phosphatase SHP-1 plays an important role for vascular haemostasis in TNFα-induced inflammation in vivo E Koch, J Pircher, T Czermak, E Gaitzsch, S Alig, H Mannell, M Niemeyer, ... Mediators of inflammation 2013, 2013 | 15 | 2013 |
| Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020; 10: 440–459. doi: 10.1158/2159-8290 P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ... CD-19-0116.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 14 | |
| Blogging medical students: A qualitative analysis S Pinilla, LT Weckbach, SK Alig, H Bauer, D Noerenberg, K Singer, ... GMS Zeitschrift für Medizinische Ausbildung 30 (1), 2013 | 13 | 2013 |
| Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models S Alig, V Jurinovic, M Shahrokh Esfahani, S Haebe, V Passerini, ... Blood Advances 4 (18), 4451-4462, 2020 | 11 | 2020 |
